Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

Novavax Inc. closed 61.59% short of its 52-week high of $17.81, which the company achieved on July 26th.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of Novavax (NasdaqGS:NVAX) with a Sell recommendation. Analyst Price Forecast Suggests 141.82% Upside As of June 2, 2025, the ...

Novavax (NVAX) stock dropped after Citi issued a Sell rating, citing concerns over its respiratory vaccine-focused pipeline. Read more here.

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...